Cases

ORDER OF COURT The various groups of plaintiffs have collectively filed three petitions for panel rehearing and two for rehearing en banc, raising various objections to the panel opinion. This order deals primarily with the petitions for panel rehearing. None of them has merit. End-Payor Class’s Petition The End-Payor Class, seeking only panel rehearing, argues that we must remand the case with

MEMORANDUM OPINION FARNAN, District Judge. AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, IPR Pharmaceuti*393cals Inc. and Shionogi Seiyaku Kabushiki Kaisha (collectively, “Plaintiffs”) brought this action against several different generic drug manufacturers, Mylan Pharmaceuticals Inc., Sun Pharmaceutical Industries, Ltd., Par P

TJOFLAT, Circuit Judge: I. These cases involve payments made by health insurers1 for the prescription drug Seroquel, an antipsychotic medication2 manufactured and marketed in the United States by AstraZeneca Pharmaceuticals LP (“AstraZeneca”). Seroquel has received Food and Drug Administration (“FDA”) approval for the treatment of schizophrenia a

MEMORANDUM OPINION SUE L. ROBINSON, District Judge I. INTRODUCTION On February 15, 2010, relator Rose-Marie De Souza (“De Souza”) filed this qui tam action against defendants AstraZene-ca PLC and AstraZeneca Pharmaceuticals LP’s (“collectively AstraZeneca”) alleging False Claims Act (“FCA”) violations relating to the promotion of Crestor® (“the original De Souza complaint”). (D.I.l) On

[PUBLISH] IN THE UNITED STATES COURT OF APPEALS FOR THE ELEVENTH CIRCUIT FILED ________________________ U.S. COURT OF APPEALS ELEVENTH CIRCUIT No. 08-16851 MARCH 11, 2011 ________________________ JOHN LEY CLERK D. C.

12-3654 Martinez v. Bloomberg LP 1 UNITED STATES COURT OF APPEALS 2 FOR THE SECOND CIRCUIT 3 4 August Term, 2012 5 6 (Argued: June 26, 2013 Decided: January 14, 2014) 7 8 9 Docket No. 12-3654-cv 10 11 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Opinion & Order BARBARA S. JONES, District Judge. *387TABLE OF CONTENTS INTRODUCTION. CO CO o I. The Parties. CO CO o II. The Patents-In-Suit. 03 05 CO A. Patent Ownership. CO CO III. The Pleadings. CO CO A. Complaint Against Mylan/Esteve.

Opinion and Order BARBARA S. JONES, District Judge. TABLE OF CONTENTS INTRODUCTION ..............................................................303 I. The Parties .............................................................304 A. Teva ................................................................304 B.

768 F.Supp.2d 420 (2011) Samuel DEUTSCH, individually and as Administrator of the Estate of Helene Deutsch, Plaintiff, v. NOVARTIS PHARMACEUTICALS CORPORATION, Defendant. Beth Forman, individually and as Executrix of the Estate of John Napolitano, Plaintiff, v. Novartis Pharmaceuticals Corporation, Defendant. Nos. 09-CV-4677 (ADS)(WDW), 09-CV-4678 (ADS)(WDW). United States District Court, E

715 F.Supp.2d 297 (2010) Shereen KOCH, Plaintiff, v. I-FLOW CORP., Hospira, Inc., APP Pharmaceuticals, LLC, APP Pharmaceuticals, Inc., Abraxis Bioscience, LLC, Abraxis Bioscience, Inc., Astrazeneca Pharmaceuticals LP and Astrazeneca LP, Defendants. C.A. No. 09-441 S. United States District Court, D. Rhode Island. June 7, 2010. *299

MICHAEL L. BROWN, UNITED STATES DISTRICT JUDGE Before the Court are Defendant Olympus Corporation's and Defendant Olympus Medical Systems Corporation's Motions to Dismiss for Lack of Personal Jurisdiction (Dkts. 27, 28) and all Defendants' Motions to Dismiss for Failure to State a Claim.1 (Dkts. 29, 30, 31, 32). I. Background Plaintiff Caryl Quashie is a

ORDER JAMES D. WHITTEMORE, United States District Judge BEFORE THE COURT is Defendants’ Innocutis Holdings, LLC (“Innocutis”) and Cipher Pharmaceuticals US LLC (“Cipher”) (collectively “Innocutis Defendants”) Motion to Dismiss and Memorandum of Law (Dkt. 24), which the Plaintiff opposed (Dkt. 25). Upon consideration, the Motion to Dismiss (Dkt. 24) is GRANTED in part and DENIED in part.

24-598 Mosaic Health, Inc. v. Sanofi-Aventis U.S., LLC In the United States Court of Appeals for the Second Circuit August Term 2024 Argued: May 2, 2025 Decided: August 6, 2025 No. 24-598 MOSAI

United States Court of Appeals For the First Circuit No. 22-1858 CARMEN QUINTANA-DIEPPA, Plaintiff, Appellant, v. DEPARTMENT OF THE ARMY, Defendant, Appellee. APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF PUERTO RICO [Hon. Aida M. Delgado-Colón, U.S. District Judge]

Opinion for the court filed by Circuit Judge WALLACH. Opinion concurring-in-part, dissenting-in-part filed by Circuit Judge O’MALLEY. WALLACH, Circuit Judge. The Fox Group, Inc. (“Fox”) appeals from the decision of the United States District Court for the Eastern District of Virginia granting Cree, Inc.’s (“Cree”) motion for summary judgment of invalidity of U.S. Patent No. 6,562,1

SILER, Circuit Judge: Defendant R.J. Reynolds Tobacco Company (Reynolds) appeals the district court’s final judgment following a jury verdict awarding compensatory damages in the amount of $5.9 million to the plaintiff, Thelma Aycock (Thelma), for her “loss of support and services, loss of companionship and protection, and her mental pain and suffering, as a result of her husban

KEVIN MCNULTY, United States District Judge These are consolidated Hatch-Waxman actions for infringement of United States Patent No. 8,822,438 ("the '438 patent") brought by Janssen Biotech, Inc.; Janssen Oncology, Inc.; Janssen Research & Development, LLC (collectively, "Janssen"); and BTG International Ltd. ("BTG"). Janssen and BTG co-own the '438 patent. The '438 patent contains twenty claims covering methods for the treatm

ORDER YOUNG, District Judge. I. INTRODUCTION Defendants AstraZeneca AB, Aktiebolaget Hassle, and Astrazeneca LP (collectively “AstraZeneca”) along with Ranbaxy Pharmaceuticals, Inc., Ranbaxy Inc. and Ranbaxy Laboratories Ltd. (collectively, “Ranbaxy”) (collectively, with AstraZeneca, the “Defendants”) move for partial summary judgment of the Direct Purchasers’ and End-Payors’ claims

No. 24-598 Mosaic Health, Inc. v. Sanofi-Aventis U.S., LLC In the United States Court of Appeals for the Second Circuit August Term 2024 Argued: May 2, 2025 Decided: August 6, 2025 Amended: October 15, 2025

MEMORANDUM OPINION AND ORDER W. KEITH WATKINS, Chief Judge. Tragically, Kenneth Seamon died from a gunshot wound to the chest inflicted by his own Remington 700 rifle while he was hunting alone from a deer stand thirteen-feet high in a tree. The rifle was found on the ground beneath the unfortunate hunter, with a rope tied to the barrel, a spent shell in the chamber, and the safety “off’ (in t